Key result
ADMA increases bovine pulmonary endothelial cell viability ~30% by inhibiting NO and enhancing urea production.
Why the study?
The effects of asymmetric dimethylarginine (ADMA) on arginase activity and cellular proliferation in pulmonary endothelial cells were unclear, particularly its role in nitric oxide synthase inhibition and arginase-mediated pathways.
Population
Bovine arginase and bovine pulmonary arterial endothelial cells
Comparison
ADMA treatment vs control or L-arginine alone
Design
In vitro activity assays and cell culture experiments
Follow-up
48 h
Authors
Loading...
Does not alter clinical practice; leaves open ADMA's role in endothelial viability for in vivo validation.
p-value: p=< 0.003
ADMA acts as a pro-proliferative agent in pulmonary endothelial cells by inhibiting NO production and enhancing urea production without inhibiting arginase, suggesting a pathophysiological role in pulmonary hypertension.
Chen et al. (2014) studied this question. Asymmetric dimethylarginine (ADMA) vs. Control was evaluated on Nitric oxide (NO) and urea production, and cell viability (p=< 0.003). In bovine pulmonary arterial endothelial cells, ADMA inhibited NO production and enhanced urea production (P<0.003), resulting in an approximately 30% greater number of viable cells after 48 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: